Christopher Semsarian
Overview
Explore the profile of Christopher Semsarian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
364
Citations
8114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
A rare splice-site variant in TNNT2: the need for ancestral diversity in genomic reference data sets
Butters A, Thomson K, Harrington F, Henden N, McGuire K, Byrne A, et al.
Eur Heart J
. 2025 Mar;
PMID: 40038847
No abstract available.
2.
Butters A, Arnott C, Sweeting J, Claggett B, Cuomo A, Cuomo A, et al.
Circ Genom Precis Med
. 2025 Jan;
18(1):e004641.
PMID: 39851041
Background: Females with hypertrophic cardiomyopathy present at a more advanced stage of the disease and have a higher risk of heart failure and death. The factors behind these differences are...
3.
Ranpura G, Holliday M, Li S, Ross S, Singer E, Fraser S, et al.
Stem Cell Res
. 2025 Jan;
83:103650.
PMID: 39826349
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited cardiac disease characterised by adrenergic-induced arrhythmias. The leading causes of CPVT are pathogenic variants in cardiac ryanodine receptor 2 (RYR2) and rarely,...
4.
Isbister J, Strocchi M, Riedy M, Yeates L, Gray B, Singer E, et al.
Heart Rhythm
. 2024 Dec;
PMID: 39675648
Background: Hydroquinidine reduces arrhythmic events in patients with Brugada syndrome (BrS). The mechanism by which it exerts antiarrhythmic benefit and its electrophysiological effects on BrS substrate remain incompletely understood. Objective:...
5.
Meisner J, Renberg A, Smith E, Tsan Y, Elder B, Bullard A, et al.
Circulation
. 2024 Dec;
PMID: 39633578
Background: Classically, hypertrophic cardiomyopathy (HCM) has been viewed as a single-gene (monogenic) disease caused by pathogenic variants in sarcomere genes. Pathogenic sarcomere variants are individually rare and convey high risk...
6.
Patel N, Shetty N, Pampana A, Gaonkar M, Vekariya N, Li P, et al.
Mayo Clin Proc
. 2024 Nov;
99(12):1933-1944.
PMID: 39530964
Objective: To evaluate sex-associated differences in the short- and long-term outcomes of patients with hypertrophic cardiomyopathy (HCM) undergoing septal myectomy and alcohol septal ablation. Methods: This retrospective cohort study used...
7.
Isbister J, Tadros R, Raju H, Semsarian C
Nat Cardiovasc Res
. 2024 Nov;
3(11):1274-1283.
PMID: 39487366
The inherited cardiomyopathies exhibit a broad spectrum of disease, with some patients remaining asymptomatic throughout life, while, for others, the first symptom of disease is sudden cardiac death at a...
8.
Asatryan B, Murray B, Tadros R, Rieder M, Shah R, Sharaf Dabbagh G, et al.
J Am Heart Assoc
. 2024 Oct;
13(21):e033557.
PMID: 39424414
Precision medicine, which among other aspects includes an individual's genomic data in diagnosis and management, has become the standard-of-care for Mendelian cardiovascular disease (CVD). However, early identification and management of...
9.
Healy J, Youssef A, Sawant S, Orchard J, Rehan R, Van Vuuren R, et al.
Heart Lung Circ
. 2024 Oct;
33(12):1693-1698.
PMID: 39389859
Background & Aim: SARS-CoV-2 infection is associated with increased cardiovascular (CV) morbidity and mortality, manifesting as increased adverse outcomes in the first 30 days, extending to 12 months. This study...
10.
Maurizi N, Antiochos P, Owens A, Lakdwala N, Saberi S, Russell M, et al.
Circulation
. 2024 Oct;
150(17):1377-1390.
PMID: 39355918
Background: Septal reduction therapy (SRT) provides substantial symptomatic improvement in patients with obstructive hypertrophic cardiomyopathy (HCM). However, long-term disease course after SRT and predictors of adverse outcomes have not been...